Involvement of 1,25D3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells.

In addition to classical roles in calcium homeostasis and bone development, 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] inhibits the growth of several cancer types, including breast cancer. Although cellular effects of 1,25(OH)2D3 traditionally have been attributed to activation of a nuclear vitamin D receptor (VDR), a novel receptor for 1,25(OH)2D3 called 1,25D3-MARRS (membrane-associated, rapid response steroid-binding) protein was identified recently. The purpose of this study was to determine if the level of 1,25D3-MARRS expression modulates 1,25(OH)2D3 activity in breast cancer cells.

Mechanism of 24,25-dihydroxyvitamin D3-mediated inhibition of rapid, 1,25-dihydroxyvitamin D3-induced responses: role of reactive oxygen species.

In intestine, 24,25(OH)(2)D(3), which is made under conditions of calcium-, phosphate-, and 1,25(OH)(2)D(3) sufficiency, inhibits the stimulatory actions of 1,25(OH)(2)D(3) on phosphate and calcium absorption. In the current work, we provide evidence that 24,25(OH)(2)D(3)-mediated signal transduction occurs mechanistically through increased H(2)O(2) production which involves binding of 24,25(OH)(2)D(3) to catalase and resultant decreases in enzyme activity. Physiological levels of H(2)O(2) mimicked the action of 24,25(OH)(2)D(3) on inhibiting 1,25(OH)(2)D(3)-stimulated phosphate uptake in isolated enterocytes.